estrogen receptor ␣ (ESR1) gene. 3 In particular, polymorphisms defined by the restriction enzymes XbaI (dbSNP [database of single-nucleotide polymorphisms]: rs9340799) and PvuII (dbSNP: rs2234693) in the first intron of ESR1 have been evaluated to date in approximately 40 studies, with inconclusive results. These 2 polymorphisms are 46 base pairs apart and in strong linkage disequilibrium with a microsatellite TA-variable number of tandem repeats (VNTR) polymorphism 4 (dbSNP: rs3138774) situated 2.1 kb upstream in the ESR1 promoter region. The role of this VNTR in osteoporosis outcomes is controversial, and interpretation is further limited by analytic inconsistencies across published reports. [4] [5] [6] [7] [8] [9] There is increasing recognition that, given the common lack of replication of results of small studies, [10] [11] [12] the delineation and establishment of common genetic risk factors for complex multigenetic disorders, such as osteoporosis, requires large-scale investigations to clarify subtle, but clinically important, genetic effects. 12, 13 Standardization is also essential to avoid misinterpreting as genuine genetic variability whatever differences between study teams are caused by analytical inconsistencies. We report the results of a collaborative study using standardized genotyping methodology on 18 917 individuals, which tests the contribution of these 3 common ESR1 polymorphisms and haplotypes thereof on BMD and fractures.
METHODS
TheGENOMOS(GeneticMarkersforOsteoporosis) project involves the study of several candidate gene polymorphisms in relation to osteoporosis-related outcomes in approximately 20000 individuals drawn from 8 European centers.
14 Participating teams contributed information on sex, age, height, weight, TA genotype (numberofTArepeatsineachallele),XbaI genotype, PvuII genotype, BMD at lumbar spine (L2-4) and femoral neck (in g/cm 2 ), fractures at any site, vertebral fractures, and menopausal status.
The 2 largest cohorts in the metaanalysis (Rotterdam and Aberdeen) genotyped their entire population, whereas other cohorts generally excluded women with secondary causes of osteoporosis or those receiving drugs that could affect bone metabolism. Study design aspects for each cohort in the consortium are available from the author on request. All participating centers have received institutional review board or ethics committee approval according to their local regulations, and participant informed consent has been obtained according to the requirements of each center.
Genotyping
Genotyping for the 3 polymorphisms was performed in different centers by using polymerase chain reaction-restriction fragment-length polymorphism, singlebase extension sequencing and 5Ј nuclease Taqman assays for the XbaI and PvuII polymorphisms and capillary electrophoresis for TA-VNTR. [5] [6] [7] For XbaI and PvuII, X and P denote the absence of the respective restriction sites (G allele and C allele, respectively).
Each center checked its own genotyping by reanalyzing at least 5% of the samples with random selection. To ensure standardization between centers, 50 randomly selected samples from 1 center (Rotterdam) were sent in blinded fashion to all the other cohorts for independent analysis. Results were assembled and compared at the coordinating center. For XbaI and PvuII, only 1 sample gave discrepant results for XbaI in 1 cohort. For the TA repeats, 2 cohorts systematically estimated 1 fewer repeat, and 1 estimated systematically 2 fewer repeats. Thus, readings were adjusted in these cohorts by adding 1 or 2 repeats, respectively. Aside from these systematic differences, 21 of the allele determinations across cohorts did not agree exactly with the predominant determination, but with the exception of 6 alleles (error rate Ͻ1%), the difference was less than 4 repeats. No data were obtained for TA repeats in one study (Cambridge), whereas in another study (Florence) TA repeats had been determined with a different method that showed extensive differences in the pilot samples.
Thus, these data were not considered in any analyses. Hardy-Weinberg equilibrium was checked on all data.
BMD Measurements
Bone mineral density was assessed by dual-energy x-ray absorptiometry with Hologic devices in the Barcelona, DOPS (Danish Osteoporosis Study), Aarhus, and Florence studies, Norland in the Aberdeen study, Lunar DPX-L in Rotterdam, and a variety of devices crosscalibrated with the European Spine Phantom in the Oxagen and Cambridge cohorts. 15 Syntheses of BMD data across studies always include also a study effect that would account both for genuine differences in populations and potential systematic differences between these devices. The results of the meta-analysis for BMD should be interpreted with emphasis on the BMD differences between the contrasted genotypes and haplotypes and not on the absolute BMD values.
Definitions and Outcomes
We analyzed genotypes for each of the 3 polymorphisms and long-range haplotypes (LRHs) by combining all 3 polymorphisms. The microsatellite genotypes were clustered in 2 groups of alleles according to the bimodal appearance of the composite distribution of the number of repeats. 4, 5 The low-repeat number group (L) was defined to extend up to the trough of the distribution, and alleles with higher numbers of repeats were grouped in the high-repeat number group (H). The resulting genotypes are HH, HL, and LL. Long-range haplo-
were imputed by using the PHASE program. 16 The main outcomes included lumbar spine BMD; femoral neck BMD; any recorded fractures based on clinical history or radiographic evaluation, as defined in each study; and vertebral fractures based on clinical or radiographic evaluation, according to the criteria of McCloskey et al. 17 Prevalent fractures (at BMD determination) were considered in all cohorts. Data on incident fractures For all analyses, data in each cohort were first split according to sex. In all studies participants were unrelated, with the exception of Oxagen pedi- HH, both alleles with Ͼ18 repeats; HL, heterozygotes; LL, both alleles with Յ18 repeats; NA, not applicable; ellipses, no data available. *Reported percentages are estimated based on individuals with available data for the respective characteristic. All Oxagen data are shown (not just those pertaining to the randomly selected sample including only 1 subject per pedigree). Data on 27 men from Florence are not shown here and were not included in the data synthesis, given the very small sample size. †Measured as weight in kilograms divided by the square of height in meters. ‡At any time up to BMD measurement. §Physical activity/ability data were measured in different scales capturing various abilities (in the Rotterdam and Cambridge cohorts) and/or activities (in the Aberdeen, Oxagen, DOPS, and Cambridge cohorts), and thus the scales and range of values are different, so they should not be compared between cohorts. All adjusted analyses using these indices were performed first within each cohort, and then the adjusted estimates were synthesized.
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Analyses
For each genotype of interest, we estimated the unadjusted mean BMD and standard deviation in each study. We then synthesized BMD differences between genotype contrasts across studies by using fixed-and random-effects general variance models. 18 Betweenstudy heterogeneity was assessed by the Q statistic (considered significant for PϽ.10). Random-effects models incorporated the between-study heterogeneity and allowed for a different effect in each population. 18 In the absence of between-study heterogeneity, fixed and random effects are similar.
We also performed analyses adjusting for the potential independent effect of each polymorphism, as well as age, weight, and height, plus menopausal status and any hormone therapy for women. Separate adjusted analyses were performed for the genotypes of each polymorphism and for the combinations of LRHs stemming from the 2 most common LRHs (A and E), ie, comparing individuals with 2, 1, or no copies of haplotype A and with 2, 1, or no copies of haplotype E. We considered study as a random factor and allowed study ϫ genotype (or haplotype) interactions to account for potentially variable genetic effects across studies. The overall significance of the genetic effects was evaluated with an F test for betweenparticipant effects. Marginal means were also obtained. P values estimated for the comparison of estimated marginal means tended to be smaller and should be interpreted with more caution.
For fractures, we estimated the number of individuals in each genotype and haplotype group of interest, and pairwise genotype and haplotype comparisons were performed by estimate of an odds ratio (OR) in each study. Genotype analyses investigated recessive and dominant models for each polymorphism, and haplotype contrasts were based on the 2 most common LRHs (A and E). In each analysis, ORs were evaluated for between-study heterogeneity by using the Q statistic (considered significant for PϽ.10) and then synthesized with the Mantel-Haenszel (fixedeffects) and DerSimonian and Laird (random-effects) methods. 18 We also performed sensitivity analyses limited to incident fractures, limited to no-trauma/ low-energy-trauma fractures, and limited to women who had not received hormone therapy. Adjusted logistic regression analyses were also performed by considering age, height, weight, and menopausal status for women, as well as BMD. Sensitivity analyses were performed also for the adjusted estimates after further adjusting for indices of physical activity and ability. Data on different such indices were available for the 4 largest cohorts (Rotterdam, Aberdeen, Oxagen, and DOPS) and for Cambridge.
Analyses were conducted using SPSS version 11.0 (SPSS Inc, Chicago, Ill) and Meta-Analyst (Joseph Lau, Boston, Mass). All reported P values are 2-tailed and unadjusted for multiple comparisons.
RESULTS

Assembled Database
Data on 18 917 individuals were assembled, of whom 14622 were women (3555 with current or past use of hormone therapy) (TABLE 1). Data on lumbar spine BMD, femoral neck BMD, any fractures, and vertebral fractures were available on 16370, 15926, 18841, and 14039 participants, respectively. Across the database, age quartile cutoffs were 47.4, 50.6, 58.0, and 69.0 years for women and 56.5, 62.1, 67.3, and 73.8 years for men. The database included 4952 individuals with any fracture and 1072 with vertebral fractures. There were 1779 individuals with incident fractures, the vast majority derived from the Rotterdam (n=1260) and Aberdeen cohorts (n=489). Only the Rotterdam cohort had a meaningful number of analyzable incident radiographically screened vertebral fractures (n=176). There were 2536 participants with notrauma/low-trauma fractures across the 7 cohorts with relevant data (excluding Aberdeen). Standardized data on XbaI, PvuII, and TA repeat genotypes were obtained in 16147, 16135, and 10902 individuals, respectively (Table 1 ). All 3 polymorphisms were in strong linkage disequilibrium with each other. The distribution of TA repeats was consistently bimodal in all studies, and overall the trough of the distribution was clearly seen at 19 repeats (FIGURE 1) . For all cohorts, the A haplotype (x-p-L) accounted consistently for about half of the alleles (range, 47.1% to 53.4%) and the E haplotype (X-P-H) for al- In unadjusted analyses, none of the 3 polymorphisms was statistically significantly associated with BMD in the lumbar spine or in the femoral neck for any of the tested genotype contrasts (FIGURE 2 and FIGURE 3) , with the exception of a slightly higher femoral neck BMD with XX as compared with xx (statistically significant at PϽ.05 by fixedeffects only). There was no statistically significant between-study heterogeneity for any of the comparisons (heterogeneity PϾ.10 for all). The estimated differences in BMD were 0.01 g/cm 2 or less for all genetic contrasts (Figure 2 and Figure 3) . The results were similar when limited to women only, with no significant betweenstudy heterogeneity and maximal estimated differences in the same range. The more sparse data on men were consistent with this picture, but estimates had more uncertainty (Figure 2 and Figure 3 ). Analyses adjusted for age, height, weight, hormone therapy, and menopausal status also showed that none of the 3 polymorphisms had a statistically significant association with BMD (not shown in detail). The typical trend for all these analyses in- overall and for women.
Results were similar using haplotypes (not shown in detail). The adjusted differences in BMD between all genetic contrasts in women were always 0.01 g/cm 2 or less at either skeletal site (with maximal trends typically showing a higher BMD in E haplotype homozygotes). No clear differences were observed in men. Interactions of age or menopausal status with genotype were not statistically significant for any of these analyses (data not shown).
Fracture Risk
Genotype Analyses. For recessive and dominant models of genetic contrasts (TABLE 2), there was no statistically significant between-study heterogeneity for any of the comparisons either for all fractures or for vertebral fractures alone (heterogeneity PϾ.10). Thus, fixed-and random-effects results were similar, although in a few cases random effects were somewhat more conservative in terms of the level of statistical significance (Table 2) .
There was a highly significant protection conferred by the XX genotype against the overall fracture risk, with approximately 20% reduction in the odds (Figure 4 , PϽ.001 by fixed effects and P=.02 by random effects) and no difference in the fracture risk between Xx and xx (fixed-effects OR, 1.11; 95% CI, 0.96-1.28); dominant models also showed significant protective effects in the absence of xx, pp or LL ( Table 2) . Results were largely consistent for women and men.
Haplotype Analyses.The results of haplotype contrasts (TABLE 3) were consistent with the results of genotype contrasts. There was no significant between-study heterogeneity for any of the analyses (heterogeneity PϾ.10). When all fractures were considered, there was 20% reduction in the odds of fractures in women homozygous for the E haplotype ( Figure 4) . For vertebral fractures, 30% to 50% odds reductions were observed with either homozygosity for E haplotype or lack of homozygosity for the A haplotype (Figure 4 ), and differences between these 2 genetic models were subtle.
Sensitivity and Adjusted Analyses
Analyses limited to incident fractures suggested a similar effect for XX in women: OR, 0.83; 95% CI, 0.68-1.01; P = .07 for any incident fracture (OR, 0.77; P=.04 for the Rotterdam cohort, in which a systematic effort was made to record radiographically vertebral fractures) and 0.54 (95% CI, 0.26-1.13) for radiographically screened incident vertebral fractures (Rotterdam). Data on men (from the Rotterdam cohort) showed no effect, but they were limited and thus inconclusive (OR, 0.99; 95% CI, 0.65-1.51 and 0.89; 95% CI, 0.38-2.09, respectively, for any fracture and vertebral fractures).
Analyses limited to no-trauma/lowenergy-trauma fractures suggested a similar effect for XX in women (OR, 0.74; 95% CI, 0.61-0.90; P=.002 by fixed effects and OR, 0.79; 95% CI, 0.60-1.03; P=.08 by random effects, with no significant between-study heterogeneity). Data on men showed no effect, but they were limited and thus inconclusive (OR, 1.01 by fixed and random effects).
Analyses excluding women who had received any hormone therapy also showed a strong protective effect for XX both for any fracture (OR, 0.71; 95% CI, 0.61-0.84; PϽ.001, with no between-study heterogeneity) and for vertebral fractures (OR, 0.60; 95% CI, 0.45-0.82; P =.001 by fixed effects and OR, 0.65; 95% CI, 0.46-0.92; P=.002 by random effects, with no significant between-study heterogeneity).
After adjustment for age, height, weight, and menopausal status, the OR for any fractures in women and men with the XX genotype vs Xx and xx was 0.81 (95% CI, 0.71-0.93; P =.002) and 0.91 (95% CI, 0.70-1.18; P = .48), respectively. The respective adjusted ORs for vertebral fractures were 0.65 (95% CI, 0.49-0.87; P=.003) and 0.84 (95% CI, 0.51-1.37; P=.48). After further adjustment for BMD values, the estimates remained largely unchanged. For example, for women the OR for any fractures remained 0.81 (95% CI, 0.71-0.93; P=.003) after adjustment for lumbar spine BMD and 0.83 (95% CI, 0.72-0.95; P = .006) after adjustment for femoral neck BMD, whereas after adjustment for lumbar spine BMD, the OR for vertebral fractures became 0.61 (95% CI, 0.45-0.82; P=.001). With fur- Point estimates and 95% confidence intervals (CIs) are shown for the odds ratio in each study. At the bottom of the graphs, summary estimates of the odds ratios and their 95% CIs are given by fixed-effects and random-effects models for the total database and for women only.
within each center to circumvent between-center differences in the type or model of densitometer used. In any case, the observed 20% to 40% reduction in the risk of fractures we observed would correspond to BMD differences of 0.030 to 0.080 g/cm 2 in epidemiologic cohorts, 19 which should have been easily detectable, given the sample size of almost 20000 individuals studied here. Nonetheless, clinical trials of osteoporosis treatments have suggested that fracture risk reduction may be disproportionately large compared with the corresponding changes in BMD. 20, 21 For example, in the Fracture Intervention Trial, changes in spine BMD explained only 16% of the reduction in the risk of vertebral fracture with alendronate. 22 Our findings are consistent with the hypothesis that the XbaI polymorphism influences fracture risk independent of BMD, even though BMD would have been a plausible biological mediator of the clinical effect for polymorphisms involved in the estrogen pathway. Possibilities include effects on bone quality, bone geometry, bone turnover, or other nonskeletal risk factors for fracture, such as decreased cognition or muscle strength. These candidate mediators need to be better studied, and there is a rapidly increasing literature on pleiotropic actions of ESR1 on various outcomes. [23] [24] [25] [26] Whatever the mechanism, the observed association has potential clinical relevance because it indicates that genotyping for the ESR1 XbaI polymorphism provides information on fracture risk that cannot be obtained by BMD measurements alone.
From a methodologic point of view, our study had the advantage of using individual participant data to allow consistent standardization of definitions, measurements, and genetic contrasts. Sampling and systematic errors are a threat to molecular studies. 27 We ensured the consistency and reliability of genotype results across the participating cohorts. Eventually, the results from all the diverse cohorts included in our consortium were similar, and there was no significant between-study heterogeneity detected in any of the analyses of interest. Between-study heterogeneity is observed in about half the cases in which different teams publish data on the same putative gene-disease association. 10, 13 Sometimes this heterogeneity may be due to technical differences and lack of standardization across different centers rather than to genuine genetic diversity. Furthermore, although our consortium design does not accommodate all previously published data, these are limited 3 compared with the evidence that we generated. A meta-analysis in which genotyping is performed prospectively is immune to the problems of publication bias 28 because all prospective, standardized genotyping results are eventually included in the analysis and inclusion is not determined by the direction or strength of the findings. Publication bias against studies that find no significant association may be a problem in genetic association studies 13 and may be another reason for the occurrence of variability among the results of studies published in the literature.
The XbaI and PvuII polymorphic sites are located in the first intron of the ESR1 gene, and so far their functional consequences are unknown. However, introns may contain regulatory elements. For example, the PvuII polymorphism is located within a potential bMyb binding site with regulatory effects on a reporter gene. 29 In the absence of definitive evidence for the functionality of these ESR1 variants, more research is needed on the potential biological pathways that they may affect. Alternatively, other polymorphic sites in strong linkage disequilibrium with those that we studied may be functional variants affecting receptor structure or, more likely, messenger RNA and protein expression. A comprehensive analysis of the ESR1 gene might require the genotyping of a large number of gene variants. However, it is impractical to perform meta-analyses of such large scale on an extended number of unselected polymorphisms; targets for obtaining large-scale genetic evidence should be selected carefully according to preliminary smaller studies, as in this case. Osteoporosis risk may also be modulated by a large number of genetic markers beyond ESR1, including polymorphisms of the vitamin D receptor (VDR) gene, 30 the collagen I ␣ 1 (COLIA1) gene, 31 and several other candidate genes. 2 Although the clinical impact of each implicated gene polymorphism is modest, the cumulative effect may be large. Moreover, clarification of the role of these genetic variants with large-scale evidence may give us important biological insights, such as the extent to which effects on fractures diverge from BMD effects. 
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